18 Alzheimers Disease Clinical Trials in Santa Monica, CA (2026)

Q: How do I join a clinical trial in Santa Monica?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you.

Recruiting Alzheimers Disease Studies in Santa Monica

NCT03486873Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

Santa Monica, CAPHASE33,500 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06493552Recruiting

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate add...

Santa Monica, CAPHASE2700 participantsVasgene Therapeutics, Inc

View Study Details

NCT06112314Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

Santa Monica, CAPHASE3680 participantsImmunocore Ltd

View Study Details

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

Santa Monica, CAPHASE1630 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06586515Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-m...

Santa Monica, CAPHASE1630 participantsEli Lilly and Company

View Study Details

NCT05123482Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents...

Santa Monica, CAPHASE1460 participantsAstraZeneca

View Study Details

NCT06510374Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)...

Santa Monica, CAPHASE3454 participantsFerring Pharmaceuticals

View Study Details

NCT03138161Recruiting

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB based on preliminary results of the Checkma...

Santa Monica, CAPHASE1250 participantsSarcoma Oncology Research Center, LLC

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

Santa Monica, CAPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Santa Monica, CAPHASE1223 participantsTakeda

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Santa Monica, CAPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT04421820Recruiting

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and...

Santa Monica, CAPHASE1220 participantsBold Therapeutics, Inc.

View Study Details

NCT06251310Recruiting

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with...

Santa Monica, CAPHASE1186 participantsSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

Santa Monica, CAPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT04142437Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with ...

Santa Monica, CA150 participantsBayer

View Study Details

NCT06234098Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-196...

Santa Monica, CAPHASE1100 participantsAlyssum Therapeutics

View Study Details

NCT04890613Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid t...

Santa Monica, CAPHASE152 participantsSenhwa Biosciences, Inc.

View Study Details

NCT05023018Recruiting

NEO100 and High-Grade Meningioma

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patie...

Santa Monica, CAPHASE230 participantsNeonc Technologies, Inc.

View Study Details

About Alzheimers Disease Clinical Trials in Santa Monica

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 18 alzheimers disease clinical trials recruiting participants in Santa Monica, CA. These studies are seeking a combined 8,889 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Vasgene Therapeutics, Inc, Immunocore Ltd and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alzheimers Disease Clinical Trials in Santa Monica — FAQ

Are there alzheimers disease clinical trials in Santa Monica?

Yes, there are 18 alzheimers disease clinical trials currently recruiting in Santa Monica, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Santa Monica?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you about next steps.

Are clinical trials in Santa Monica free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Santa Monica studies also compensate for your time and travel.

What alzheimers disease treatments are being tested?

The 18 active trials in Santa Monica are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.

Data updated October 12, 2026 from ClinicalTrials.gov